Sarcomas, a diverse group of malignancies, exhibit substantial heterogeneity in both biological behavior and microenvironment, influencing their response to immunotherapy. Although pembrolizumab is ...

Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...

In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

Please provide your email address to receive an email when new articles are posted on . Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for ...

The addition of pembrolizumab to chemotherapy in high-risk early triple-negative breast cancer (TNBC) improves cancer outcomes. However, pembrolizumab induces varied immune-related adverse events ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...

The median progression-free survival was 11.2 and 7.8 months with sacituzumab govitecan plus pembrolizumab and chemotherapy plus pembrolizumab, respectively. Sara M. Tolaney, MD, from the Dana-Farber ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial ...